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Abstract
Background: Data on risk factors of recurrent bacterial vaginosis (RBV) are still scarce. We used data from female
sex workers (FSW) participating in a randomized controlled microbicide trial to examine predictors of BV recurrence.
Methods: Trial’s participants with at least an episode of BV which was treated and/or followed by a negative BV
result and at least one subsequent visit offering BV testing were included in the analysis. Behavioural and medical
data were collected monthly while laboratory testing for STI and genital tract infections were performed quarterly.
The Andersen-Gill proportional hazards model was used to determine predictors of BV recurrence both in bivariate
and multivariate analyses.
Results: 440 women were included and the incidence rate for RBV was 20.8 recurrences/100 person-months (95%
confidence interval (CI) =18.1–23.4). In the multivariate analysis controlling for the study site, recent vaginal
cleansing as reported at baseline with adjusted hazard-ratio (aHR)=1.30, 95% CI = 1.02-1.64 increased the risk of BV
recurrence, whereas consistent condom use (CCU) with the primary partner (aHR=0.68, 95% CI=0.49-0.93) and
vaginal candidiasis (aHR=0.70, 95% CI=0.53-0.93), both treated as time-dependent variables, were associated with
decreased risk of RBV.
Conclusion: This study confirms the importance of counselling high-risk women with RBV about the adverse
effects of vaginal cleansing and the protective effects of condom use with all types of partners for the prevention
of sexually transmitted infections, including BV. More prospective studies on risk factors of BV recurrence are
warranted.
Trials registration: NCT00153777
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Background
Bacterial vaginosis (BV) is the most common vaginal in-
fection in women of reproductive age. Its prevalence var-
ies from 9% to 50% [1,2] and may reach 70% among
female sex workers (FSW) [3]. Besides its high frequency,
BV is associated with many adverse health outcomes
[4-10] including pelvic inflammatory disease, unfavourable
pregnancy outcomes and recently HIV. BV is not only as-
sociated with female acquisition of HIV [9,10] but also
with female-to-male transmission of HIV, as reported in a
recent study [7]. Though it is increasingly clear that BV
results from the replacement of the lactobacillus domi-
nated normal flora by a predominantly anaerobic flora, no
single causal agent has yet been identified. As a result,
current treatment strategy aims at restoring the balance of
the vaginal flora without specifically targeting any single
causal agent. This may explain the high rate of treatment
failure and recurrence that constitutes a major challenge
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for the clinical management and control of BV. Some au-
thors [11-14] have suggested periodic presumptive treat-
ment (PPT) as response to this challenge; however, the
high recurrence rate makes the cost-effectiveness of this
strategy questionable [15]. Knowing predictors of BV re-
currence may help identify subgroups in whom PPT may
be more efficient and prevent BV recurrences and their
subsequent adverse health outcomes.
The purpose of this study was to identify behavioural
and medical predictors of BV recurrence among women
who experienced a prior BV episode during their follow-




Settings and participants selection
We performed a secondary longitudinal analysis of data
from HIV-negative FSWs enrolled in the cellulose sulphate
(CS) trial, a double-blind randomized placebo-controlled
trial evaluating the effect of 6% vaginal CS gel on HIV
acquisition. Participant recruitment, follow-up and labo-
ratory methods are described elsewhere [16]. Briefly, the
trial recruited participants from five sites: Durban (South
Africa); Kampala (Uganda); Cotonou (Benin); Chennai
(India) and Bagalkot District (India). However, because of
the occurrence of some local changes in the standardized
method for BV laboratory diagnosis at the Durban site,
and to ensure the comparability of our findings, the
present analysis was restricted to participants from the lat-
ter four sites. Participants were FSWs who were 18 years
or older, HIV seronegative, not pregnant and not desiring
to become pregnant during their participation in the study.
The study was approved by ethics committees (EC) of the
Eastern Virginia School of Medicine, Norfolk, VA (USA),
of the fhi360, NC (USA) and of each collaborating center:
EC of the Centre hospitalier affilié universitaire de Québec
in Canada, of the Faculté des Sciences de la Santé in
Cotonou; of the National Aids Research Committee; of
the Uganda Nation Research Council for Science and
Technology; of YRG Care, Chennai, India; of the Univer-
sity of Manitoba, Winnipeg, Canada; of St. John's Medical
College, Bangalore, India; of the Indian Council of Med-
ical Research, Delhi, India and of the Medical Research
Council, Durban, South Africa.
Trial participants provided written informed consent. At
the screening visit, a questionnaire was administered to
consenting women by trained health providers, asking
about their socio-demographics, current contraceptive use,
intra-vaginal cleansing practices (products used and reason),
past history of STI and sexual behaviours (detail with the
Additional file 1). Participants were then screened for HIV,
syphilis, Neisseria gonorrhoeae, Chlamydia trachomatis, BV,
Trichomonas vaginalis and vaginal yeast. All procedures,
with the exception of the baseline questionnaire, were re-
peated at the enrolment visit (occurred within 28 days of
screening). At enrolment, eligible women were randomized
to active or placebo vaginal gel and were instructed to use
their gel before each sexual act for 12 months. The partici-
pants received intensive counselling about condom use and
were provided free condoms at each visit. Monthly behav-
ioural data were collected (detail with Additional file 2) and
pelvic exams with laboratory testing for HIV and other STI
were performed quarterly. Follow-up was planned for 12
months, but the trial was closed prematurely following an
interim analysis which suggested an increased risk of HIV
among women in the active arm.
Laboratory procedures
BV diagnosis was made locally at each study site, by
Gram stain, using the Nugent’s scoring system [17] and
according to a standardised operation procedure (SOP).
Trichomoniasis and candidiasis were diagnosed micro-
scopically on wet mount. The endocervical swabs were
tested with nucleic acid amplification tests for genital
gonococcal and chlamydial infections. For syphilis diag-
nosis, blood samples were screened with Rapid Plasma
Reagin (RPR) test and reactive samples were confirmed
with a treponemal antibody test. At the screening and
enrolment visits, HIV antibody testing was performed
using the national HIV testing guidelines in place at
each study site. For the follow-up visits, the study-
specific algorithm was used. Pregnancy tests brands var-
ied by site. All assays were conducted according to the
manufacturers’ instructions. For all curable genital tract
infections which were diagnosed, including BV, women
with symptoms were treated at the same visit, whether
lab test result was available or not (using the syndromic
approach) while others were treated once test results be-
came available, mostly in less than a week.
Definitions of some concepts and study outcome for the
present study
BV treatment
For the purpose of the present study, a BV treatment
was deemed “effective” if it was in compliance with the
2006 UK guidelines for BV treatment [18].
Positive BV result
A positive BV result was defined as a Nugent score ≥ 7.
Participants were defined as BV negative if they had a
negative test result (Nugent score < 7) or were at least at
the seventh day of the onset of an “effective BV treatment”.
Incident BV
Incident BV was defined as a positive BV result obtained
at a follow-up visit (whether scheduled or not) which was
at least 7 days from the onset of “effective BV treatment”,
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or following a negative BV result. A case of incident BV
was assumed to have occurred at the midpoint between
the date of the last negative BV result and the date of the
visit at which the incident BV was diagnosed.
BV episode
A BV episode was defined as one or multiple consecu-
tive positive BV results starting with the occurrence of
an incident BV, as defined above, and ending either at
the seventh day of an “effective BV treatment” or at the
midpoint between the date of the last positive result of
the BV episode and the date of the first negative BV re-
sult (whichever came first).
Recurrent BV (study outcome)
Recurrent BV (RBV) was defined as incident BV (as de-
scribed above) following a positive BV result obtained at
a previous visit (including the enrolment visit). A partici-
pant could have multiple recurrences during the follow-
up period.
At-risk period
Participants with prior BV (index BV) were considered
at risk of a RBV for the period spanning from the end of
the index BV episode to the beginning of the next BV
episode, or to the end of their follow-up, whichever oc-
curred first. In cases of multiple BV recurrences, periods
between BV episodes were considered as at-risk periods.
Participant selection for the present analysis
The present analysis involved trial participants who, dur-
ing follow-up (including the enrolment visit), had at
least one BV episode, followed by:
– an “effective BV treatment” and at least one
subsequent visit at which a Nugent test was
performed or;
– a visit at which a negative BV result was obtained.
Statistical methods
Participants’ baseline and follow-up characteristics are
presented as percentages for categorical variables or me-
dians along with inter-quartile ranges (IQR) for continu-
ous variables. The RBV rate was obtained by dividing
the number of RBV by the total number of person-
months at risk. The 95% confidence intervals (95% CI)
were obtained for the rate by bootstrapping 1000 sam-
ples with replacement. Variables reported in previous
studies as potential predictors of RBV were selected for
the analysis. These included socio-demographic charac-
teristics, sexual behaviours, past history of, and current
STI or reproductive tract infections.
Andersen-Gill proportional hazard models were used
to identify independent predictors of RBV (as multiple
events) by estimating hazard ratios (HR) [19]. The 95%
CI of the HR and the p-values based on these models
were derived from robust sandwich variances to account
for intra-subject dependency attributable to the multiple
recurrences that participants could experience [19].
Univariate models were fit with and without control
for study site. Variables with p-value ≤ 0.20 in the uni-
variate models controlling for study site were selected to
construct the initial (full) multivariate model. Backward
selection was used and variables which reached a signifi-
cance level of 0.05 were retained in the final multivariate
model as predictors of BV recurrence. Proportionality
and linearity hypotheses were verified for the models.
Statistical tests were two-tailed. Data were analysed with
SAS software version 9.3 (SAS Institute, Cary, NC).
Results
Baseline socio-demographic, behavioural and biological
characteristics of the participants
From July 2005 to January 2007, a total of 1491 women
were screened and 822 were enrolled at the four study
sites. Out of the 822, 440 women met the eligibility criteria
for BV recurrence as described above and were included
in the present analysis. Baseline socio-demographic, be-
havioural and biological characteristics of the participants
are summarized in Table 1.
The median age of the study population was 28 years
[inter-quartile range (IQR) = 23-35] and the median num-
ber of years in school was 7 (IQR=3-9). One hundred and
twenty-eight (29.1%) of the women reported an occupa-
tion besides commercial sex work. The median number
of sexual partners in the seven days preceding their study
entry was 8 (IQR=4-21). Seventy-three (17.6%) reported
recent (within 90 days) intra-vaginal-cleansing.
Incidence of RBV
Among the 440 women, 253 (57.5%) experienced at least
one BV recurrence during follow-up: 165 had one re-
currence; 64 had two; 18 had three and 6 had four (giving
a total of 371 recurrences). The 371 BV recurrences oc-
curred over a total at-risk-period of 1783.12 person-
months (146.56 person-years), giving an incidence rate of
20.8 recurrences/100 person-months (95% CI=18.1 – 23.4)
or 2.53 recurrences/person-year (95% CI=2.26 – 2.77).
Factors associated with RBV in univariate analysis
Baseline factors associated with RBV in univariate analysis
In univariate analysis without control for the study site,
several baseline factors were significantly associated with
RBV, as presented in Table 2. For positive associations
these include being older than 28 years, cohabiting with
a man, exerting an occupation besides sex work, recent
intra-vaginal cleansing [since the visit preceding that of
baseline (for women with BV at the enrolment visit in
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the trial, the preceding visit was the screening visit)],
having an STI history and having had oral or anal sex
with other partners in the 30 days prior to the baseline
visit. In contrast, having been to school for at least six
years, consistent condom use (CCU) with the primary
partner in the past seven days and surprisingly, higher
number of sexual partners, were inversely associated
with RBV. There was a trend towards a positive associ-
ation between use of intra-uterine device and RBV, and
a negative association between hormonal contraception
and RBV, but neither was statistically significant. Treat-
ment group was not associated with BV recurrence.
After controlling for study site, only recent intra-vaginal
cleansing was significantly associated with RBV with an
adjusted HR (aHR)=1.31, 95% CI=1.03 – 1.66.
Time-dependent factors associated with RBV in
univariate analysis
Results from the univariate analysis of the associations be-
tween time-dependent variables and RBV are presented in
Table 3. Oral sex, whether with the primary or other part-
ners (whether all acts or those without condom use) was
significantly and positively associated with RBV. In con-
trast, CCU with the primary partner, the presence of a va-
ginal candidiasis in the at-risk period and high number of
sexual partners in the past seven days were inversely asso-
ciated with RBV. For CCU with the primary partner and
the presence of candidiasis, the association remained sig-
nificant after controlling for study site.
Factors associated with RBV in the multivariate analysis
Variables with p-value<0.20 in the univariate analysis
controlling for study site were included in the multi-
variate model. Recent intra-vaginal cleansing as self-
reported at the baseline visit was positively associated
with RBV, whereas CCU with the primary partner in the
past seven days and vaginal candidiasis in the at-risk
period were protective (Table 4). In addition, study site
remained significantly associated with RBV. None of the
STI or genital tract infections, other than candidiasis,
was significantly associated with RBV.
Discussion
Among these 440 HIV seronegative FSW with a BV epi-
sode at baseline, we found that 253 (57.5%) have had at
least one BV recurrence during their follow-up. The in-
cidence rate was 20.8 recurrences/100 person-months
(95% CI=18.1 – 23.4) or 2.53 recurrences/person-year
(95% CI=2.26 – 2.77).
Most prior studies on RBV looked only at the first re-
currence, in the context of treatment regimen evaluation
[20-23]. Therefore, their primary outcome was the pro-
portion of treated subjects experiencing at least one BV
recurrence in a given post-treatment length of time. This
Table 1 Baseline characteristics of 440 female sex
workers followed-up in a microbicide trial at 2 african
and 2 indian sites






Indian sites (Chennai and Bagalkot District) 133 (30.2)
Age in years 28 [23-35]
Completed years of school 7 [3-9]
Cohabiting with a man 94 (21.4)







Intra-uterine device 3 (0.7)
Female sterilization 118 (26.8)
Having a primary partner 331 (75.2)
Number of sexual partners in the past 7 days† 8 [4 – 21]
Percentage of sexual act with primary partner using
condom 100% ‡
97 (46.6)
Percentage of sexual act with other partners using
condom 100% ¶
361 (97.6)
Oral or anal sex in the past 30 days with
primary partner ©
15 (5.8)
Oral or anal sex in the past 30 days with primary
partner without condom ©
10 (4.2)
Oral or anal sex in the past 30 days with
other partners #
22 (5.0)
Oral or anal sex in the past 30 days with other
partners without condom #
8 (1.4)
History of STI at baseline 321 (72.9)
Recent intra-vaginal cleansing
(within 90 days) @
73 (17.6)
Irregular menstrual cycles 97 (22.0)
Laboratory diagnosis of STI or reproductive tract
infections at baseline:
Gonorrhoea § 27 (6.2)
Chlamydia § 28 (6.4)
Trichomoniasis ¥ 20 (4.6)
Candidiasis ¥ 112 (25.6)
*IQR =Inter-quartile range; †= missing data for 29 woman; ‡= The denominator
excludes 207 women who reported not having a primary partner with whom
they had sex in the last 7 days and 25 other who did not report on condom use;
¶ = The denominator excludes 44 women who reported not having sex with
other partners in the last 7 days and 26 other who did not report on condom
use; ©The denominator excludes 74 who reported not having a primary partner
and 25 others who did not report on anal or oral sex; # =The denominator
excludes 27 who did not report on anal or oral sex. §= missing data for 3
woman; ¥= missing data for 2 women; @= missing data for 25 women.
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Table 2 Association between baseline characteristics and incidence of bacterial vaginosis recurrence among 440
female sex workers followed-up in a microbicide trial: hazard ratios (unadjusted vs. adjusted for the study site)
Baseline factors Incidence rate of BV recurrence









Chennai/ Bagalkot District 39.5 (142/359.57) 5.27 (3.90 – 7.12) <0.0001 - -
Cotonou 28.9 (160/553.93) 3.69 (2.76 – 4.94) <0.0001 - -
Kampala (ref) 7.9 (69/869.62) 1.00 - - - -
Age (years; continuous) - 1.03 (1.01 – 1.04) 0.0004 0.99 (0.97 - 1.00) 0.1452
Age (category):
≥28 years (median) 25.8 (196/760.83) 1.52 (1.19 – 1.94) 0.0009 0.83 (0.64 - 1.07) 0.1476
<28 years 17.1 (175/1022.28) 1.00 - - 1.00 - -
Number of years in school (continuous) - 0.99 (0.95 – 1.03) 0.6279 1.02 (0.98 - 1.05) 0.2832
Years in school (category):
≥ 6 years 16.8 (151/900.52) 0.67 (0.52 – 0.86) 0.0015 1.05 (0.84 - 1.32) 0.6427
< 6 years 24.9 (220/882.60) 1.00 - - 1.00 - -
Living with a man
Yes 31.9 (95/297.70) 1.75 (1.35 – 2.26) <0.0001 0.99 (0.73 - 1.32) 0.9227
No 18.6 (276/1485.42) 1.00 - - 1.00 - -
Exerting an occupation besides
sex work
Yes 26.9 (123/457.67) 1.44 (1.10 - 1.89) 0.0076 0.89 (0.68 - 1.15)
No (Ref.) 18.7 (248/1325.45) 1.00 - - 1.00 - 0.3612
Having ever been pregnant
Yes 21.3 (354/1659.72) 1.55 (0.89 – 2.71) 0.1201 1.16 (0.73 - 1.83) 0.5249
No 13.8 (17/123.40) 1.00 - - 1.00 - -
Current contraceptive method
Female sterilization 38.2 (121/316.67) 2.21 (1.69 – 2.90) <0.0001 0.99 (0.66 - 1.51) 0.9934
Intra-uterine device 37.9 (4/10.55) 2.16 (0.90 – 5.15) 0.0837 1.14 (0.56 - 2.34) 0.7215
Injectable 11.8 (18/152.70) 0.66 (0.39 - 1.13) 0.1308 1.21 (0.69 - 2.10) 0.5095
Oral 13.1 (18/137.25) 0.73 (0.41 - 1.29) 0.2800 0.98 (0.57 - 1.70) 0.9577
None (Ref.) 18.0 (210/1165.95) 1.00 - - 1.00 - -
Recent intra-vaginal cleansing reported
at baseline
Yes 32.3 (112/347.20) 1.75 (1.34 - 2.28) <.0001 1.31 (1.03 - 1.66) 0.0279
No 18.5 (246/1326.27) 1.00 - - 1.00 - -
Number of sexual partners /last
7days (Continuous)
- 0.98 (0.97 - 0.99) 0.0003 0.99 (0.99 - 1.00) 0.4145
Number of sexual partners /last 7 days:
≥ 8 partners (median) 14.9 (159/1067.18) 0.49 (0.39 – 0.63) <0.0001 0.89 (0.67 - 1.18) 0.4079
< 8 partners 29.6 (212/715.93) 1.00 - - 1.00 - -
Having a primary partner
Yes 21.6 (289/1337.92) 1.18 (0.88 – 1.59) 0.2679 0.98 (0.75 - 1.27) 0.8825
No 18.4 (82/445.20) 1.00 - - -
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Table 2 Association between baseline characteristics and incidence of bacterial vaginosis recurrence among 440
female sex workers followed-up in a microbicide trial: hazard ratios (unadjusted vs. adjusted for the study site)
(Continued)
CCU‡ with primary partner in the
past 7 days:
Yes 17.3 (83/479.37) 0.68 (0.48 – 0.96) 0.0277 0.77 (0.56 – 1.07) 0.1236
No (ref.) 28.7 (134/466.28) 1.00 - - 1.00 - -
No primary partner or no sexual act
with him
18.4 (154/837.47) 0.74 (0.55 – 0.99) 0.0459 0.97 (0.74 - 1.28) 0.8564
CCU‡ with other partners in the
past 7 days:
Yes 20.3 (329/1620.65) 0.49 (0.19 – 1.28) 0.1467 0.86 (0.34 – 2.18) 0.7505
No (ref.) 25.1 (19/75.70) 1.00 - - - -
No sexual act with other partners 26.5 (23/86.77) 0.62 (0.22 – 1.71) 0.3556 0.96 (0.35 – 2.59) 0.9340
History of STI
Yes 27.0 (176/651.55) 1.53 (1.14 - 2.05) 0.0046 1.13 (0.86 - 1.47) 0.3864
No 17.2 (195/1131.57) 1.00 - - 1.00 - -
Anal /oral sex with primary partner/ past
30 days
Yes 29.2 (14/47.97) 1.30 (0.70 - 2.42) 0.4018 0.72 (0.38 - 1.34) 0.3011
No (Ref) 22.3 (292/1311.10) 1.00 - - 1.00 - -
Did not have primary partner 16.5 (52/314.40) 0.74 (0.52 - 1.04) 0.0800 0.99 (0.73 - 1.33) 0.9381
Anal /oral sex with primary partner
without condom
Yes 29.9 (9/30.08) 1.34 (0.68 - 2.65) 0.3951 0.78 (0.41 - 1.50) 0.4594
No (Ref) 22.3 (297/1328.98) 1.00 - - 1.00 - -
Did not have primary partner 16.5 (52/314.40) 0.73 (0.52 - 1.03) 0.0766 1.01 (0.74 - 1.35) 0.9931
Anal /oral sex with other partners/past
30 days
Yes 46.4 (28/60.32) 2.26 (1.60 - 3.18) <.0001 1.20 (0.82 - 1.74) 0.3434
No (Ref) 20.7 (330/1591.95) 1.00 - - 1.00 - -
Anal /oral sex with other partners
without condom
Yes 47.3 (10/21.15) 2.19 (1.08 - 4.44) 0.0298 1.17 (0.57 - 2.38) 0.6671
No anal or oral sex with other
partners (Ref.)
21.3 (348/1631.12) 1.00 - - 1.00 - -
History of irregular menstrual cycles
Yes 22.3 (78/349.37) 1.09 (0.80 – 1.48) 0.5733 1.11 (0.84 - 1.47) 0.4708
No 20.4 (293/1433.75) 1.00 - - 1.00 - -
Treatment group
Active gel 21.5 (178/828.88) 1.07 (0.84 – 1.38) 0.5753 0.97 (0.77 - 1.21) 0.7645
Placebo 20.2 (193/954.23) 1.00 - - 1.00 - -
Gonorrhea
Present 26.3 (31/117.82) 1.32 (0.81 - 2.12) 0.2618 1.27 (0.81 - 2.00) 0.30271
Absent 20.3 (336/1650.72) 1.00 - - 1.00 - -
Chlamydia
Present 13.4 (18/134.65) 0.63 (0.34 - 1.15) 0.1319 1.07 (0.62 - 1.85) 0.8035
Absent 21.4 (349/1633.88) 1.00 - - 1.00 - -
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makes it difficult to compare the RBV frequency in the
present study to those previously reported.
The two studies which reported BV incidence as
multiple events were sub-studies of the same trial that
evaluated the effect of PPT on the incidence of vaginal
infections [12]. The first study, which was a secondary
analysis focusing on the placebo group only, found a BV
incidence rate of 361/100 person-years over the trial
period [24]. The second study evaluated the post-trial
effect of the PPT (first 120 days post-trial) and found
RBV incidence of 260/100 person-years (95% CI=199-
340) and 358/100 person-years (95% CI=286-448) for
the intervention and placebo groups, respectively [25].
The RBV incidence of 253/100 person-years in the
present study is somewhat lower than the three others,
though only significantly for the two results reported
from the placebo group (whether in- or post-trial). This
discrepancy may be due to the fact that, unlike in the
current study where all microscopically diagnosed BV
were treated, (regardless of the presence of symptoms),
only symptomatic BV were treated in the PPT and post-
PPT studies. These two studies may have thus reported
several times some persistently asymptomatic and thus
untreated BV. Consequently we may rather be comparing
incidence of “visits with BV diagnosis” to that of RBV.
In the multivariate analysis controlling for study site,
recent vaginal cleansing, as reported at study entry, was
a risk factor for RBV, whereas CCU with the primary
partner and vaginal candidiasis were negatively associ-
ated with it.
While several previous cross-sectional or prospective
studies found that intra-vaginal cleansing increased the
risk of single BV, very few dealt with recurrent BV
[24,26,27]. Schwebke et al. reported that vaginal douch-
ing increased the risk of RBV [26], and the first sub-
study on the PPT trial data found that the risk of RBV
increased with vaginal washing frequency (p-value for
trend=0.04) [24]. These findings are consistent with our
results, though we did not collect data on vaginal wash-
ing frequency. However, some studies found no as-
sociation between vaginal douching and BV [21,27]. In
fact, although vaginal washing is a common practice, the
frequency, techniques, products used and circumstances
vary from one individual to another, and from culture to
culture. This might explain the inconsistencies in studies
results.
Compared to women who reported inconsistent con-
dom use with their primary partners in the previous seven
days, those who reported CCU were significantly at lower
RBV risk, and interestingly their aHR was similar to that
of women with no primary partner or no sexual act with
the latter. These results support the idea that consistent
and proper use of condoms may be as effective as sexual
abstinence in protecting against BV recurrence. The non-
significance of the association between CCU with other
sexual partners (clients) and RBV may be due to a lack of
statistical power resulting from the high percentage of
condom use (97.6%) reported for this subgroup of sexual
partners. Several studies have shown that CCU can re-
duce BV recurrence [24,26,28,29]. However, Yotebieng
et al. found that condom use was protective against BV
occurrence but not BV recurrence [30]. Unlike with a sin-
gle BV episode, we did not find any association between
STI or reproductive tract infections (except candidiasis)
and RBV, and neither did Klatt et al. and Myer et al.
[27,31]. However, in some studies, trichomoniasis was as-
sociated with RBV [24,32].
Vaginal candidiasis (VC) during follow-up (but not at
baseline) was inversely associated with RBV, consistent
with the results of McClelland et al. [24]. The common
explanation is that the two conditions are incompatible as
they are inversely related to vaginal pH. Another study
found that VC often preceded a BV episode though they
rarely coexisted [33]. The reason of such a chronology re-
mains unknown.
Finally, the study site exhibited a consistently strong as-
sociation with BV recurrence, independently of all other
factors, suggesting that RBV may be determined by a
more complex network of site-specific unmeasured and
probably interrelated factors. A striking finding in the
current study is the overwhelming effect of the study site
on the associations between investigated risk factors and
RBV. With the exception of recent vaginal cleansing as
self-reported at baseline, CCU with the primary partner
Table 2 Association between baseline characteristics and incidence of bacterial vaginosis recurrence among 440
female sex workers followed-up in a microbicide trial: hazard ratios (unadjusted vs. adjusted for the study site)
(Continued)
Trichomoniasis
Present 16.4 (14/85.27) 0.76 (0.35 - 1.62) 0.4720 0.90 (0.50 - 1.62) 0.7339
Absent 21.2 (357/1686.95) 1.00 - - 1.00 - -
Candidiasis
Present 21.8 (85/389.47) 1.05 (0.80 - 1.39) 0.7130 0.97 (0.72 - 1.31) 0.8678
Absent 20.7 (286/1382.75) 1.00 - - 1.00 - -
*NR =number of recurrences; § HR=Hazard ratio; ¶ CI=Confidence interval; ‡ CCU=Consistent condom use (100% of sexual acts).
Guédou et al. BMC Infectious Diseases 2013, 13:208 Page 7 of 11
http://www.biomedcentral.com/1471-2334/13/208
Table 3 Association between time-varying factors and incidence of bacterial vaginosis recurrence among 440 female
sex workers followed-up in a microbicide trial: hazard ratios (unadjusted vs. adjusted for the study site)
Time-varying Factors Incidence rate of BV recurrence
(per 100 person-months) by exposure
level (NR*/person-months)
HR§ and 95% CI¶ p-value HR§ (adjusted for study
site) with 95% CI¶
p-value
Number of sexual partners/past
7 days (continuous)
- 0.99 (0.98-0.99) 0.0142 0.99 (0.99-1.00) 0.4145
CCU‡ with primary partner in the
past 7 days:
yes 18.8 (73/387.27) 0.58 (0.42-0.80) 0.0010 0.67 (0.49- 0.93) 0.0153
No (ref.) 32.3 (113/349.28) 1.00 - - 1.00 - -
No primary partner or no
sexual act with him
17.6 (183/1039.67) 0.54 (0.42-0.71) <0.0001 0.69 (0.53- 0.88) 0.0032
CCU‡ with other partners in the past
7 days:
yes 18.8 (319/1457.60) 0.84 (0.41-1.72) 0.6353 1.33 (0.58-2.20) 0.7269
No (ref.) 24.9 (6/24.07) 1.00 - - 1.00 - -
No sexual act with other
partners
16.0 (44/274.95) 0.62 (0.29-1.36) 0.2380 0.96 (0.47-1.97) 0.9077
Oral sex with primary partner/past
30 days
yes 45.2 (11/24.35) 2.07 (1.24-3.47) 0.0054 1.10 (0.64 - 1.90) 0.7298
No 21.7 (324/1495.87) 1.00 - - 1.00 - -
No primary partner 13.8 (36/261.38) 0.62 (0.42-0.93) 0.0195 0.92 (0.65-1.28) 0.6094
Oral sex without condom with
primary partner/past 30 days
yes 46.8 (9/19.22) 2.24 (1.36-3.70) 0.0015 1.20 (0.71-2.03) 0.4934
No 21.7 (326/1501.00) 1.00 - - 1.00 - -
No primary partner 13.8 (36/261.38) 0.62 (0.42-0.92) 0.0190 0.92 (0.66-1.28) 0.6183
Oral sex with other partners/past
30 days
yes 35.6 (17/47.72) 1.70 (1.16-2.50) 0.0062 0.86 (0.56-1.32) 0.4930
No 20.6 (353/1711.97) 1.00 - - 1.00 - -
Oral sex without condom with other
partner/past 30 days
yes 45.1 (4/8.87) 2.23 (0.90-5.52) 0.0824 1.19 (0.46-3.04) 0.7193
No 20.9 (366/1750.82) 1.00 - - 1.00 - -
Gonorrhea in the at-risk-period
Present 24.5 (17/69.42) 1.18 (0.75-1.86) 0.4813 1.45 (0.87-2.416) 0.1482
Absent 20.7 (354/1713.70) 1.00 - - 1.00 - -
Chlamydia in the at-risk-period
Present 16.1 (12/74.40) 0.77 (0.43-1.37) 0.3688 1.12 (0.67-1.87) 0.6720
Absent 21.0 (359/1708.72) 1.00 - - 1.00 - -
Trichomoniasis in the at-risk-period
Present 15.7 (8/50.85) 0.73 (0.33-1.61) 0.4393 0.80 (0.37-1.71) 0.5589
Absent 20.9 (363/1732.27) 1.00 - - 1.00 - -
Candidiasis in the at-risk-period
Present 15.6 (86/552.65) 0.68 (0.53-0.87) 0.0025 0.69 (0.53-0.91) 0.0095
Absent 23.2 (285/1230.47) 1.00 - - 1.00 - -
*NR =number of recurrences; § HR=Hazard ratio; ¶ CI=Confidence interval; ‡ CCU=Consistent condom use (100% of sexual acts).
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and vaginal candidiasis (as time-dependent variables), all
the associations which were initially significant lost their
significance when controlled for study site. This suggests
strong confounding by site due to a highly variable distri-
bution of socio-demographic and medical variables across
sites. Nevertheless, the univariate association between
anal or oral sex (receiving penis in the mouth) and RBV
deserves some attention.
The role of oral or anal sex in BV occurrence is sup-
ported by several studies [32,34-37]. In a recent pro-
spective study [35], women with incident BV were more
likely to have previous colonization of anus or oral cavity
with BV-associated bacteria. In another study [34], the
risk of periodontal disease was increased among women
with BV (adjusted risk ratio =1.23; 95% CI: 1.08-1.40). In
the same study, the risk for periodontal disease was 1.28
times (95% CI: 0.97-1.69) greater for receptive oral sex
(ROS) with an uncircumcised partner, compared with
ROS with a circumcised partner [34]. In another study,
having vaginal sex after receptive anal intercourse was
linked with acquisition of BV [37].
The primary limitation of the current study resides in
assuming for some BV episodes (in the absence of test
of cure) that BV treatment, as administered per local
guidelines, became effective seven days from the onset
of the treatment. Some persistent BV may have thus
been taken as RBV and this would have resulted in an
overestimation of the RBV incidence. However the set-
ting of the cure timeline of 7 days was based on the cure
(Nugent score <7) rate of 80% to 90% generally reported
in the literature for the same duration regarding the
treatment regimens selected for our analysis [38]. Be-
cause of the relatively long periodicity of BV testing
(3 months) we may have missed some BV episodes. We
were not able to assess the effect of vaginal cleansing as
reported during follow-up, because the proportion of
women reporting the practice drastically declined over
follow-up. This decrease resulted from the consistent
counselling provided to women against vaginal cleansing
at monthly visits as part of the instructions for the use of
the study product. However, since data on vaginal cleans-
ing were self-reported, those collected during follow-up,
subsequently to several counselling sessions might be
more subject to the effect of social desirability than those
collected at study entry. Therefore, the former may be less
appropriate than the latter in assessing the effect of vagi-
nal cleansing on RBV. Also, some established BV risk
factors, such as HSV-2 infection, smoking and alcohol
consumption could not be included in the analysis be-
cause no data were collected about them in the trial.
Finally, the current analysis did not cover biological pre-
dictors of RBV such as the presence and/or concentration
of some specific BV related micro-organisms.
Nonetheless, this study presents several strengths. The
primary one is the use of Andersen-Gill proportional
risk modeling which allows for repeated events. To our
best knowledge, the present study is the third analysis
(after the first two by McClelland et al.) and the largest
one that has used this approach to investigate predictors
of RBV. Also, the consideration of BV clinical features to
work out the at-risk period, instead of using the whole
follow-up period, prevents underestimation of the RBV
incidence. Like with other infectious diseases, the subject
is not at risk for another BV episode until the previous
resolves and this should be considered when calculating
the person-time at risk (which was not done in previous
studies). Other strengths include the large sample size,
the use of the current gold standard for BV diagnosis
(Nugent score) and the high level of the quality assur-
ance system conferred by the clinical trial setting.
Conclusions
In summary, from this longitudinal analysis of data from
a randomized clinical trial, we report a relatively high
Table 4 Baseline and time-varying factors predicting bacterial vaginosis recurrence among 440 female sex workers
followed-up in a microbicide trial: adjusted hazard ratios (Multivariate model)
Factors HR§ and 95% CI¶ p-value
Study sites:
Chennai/Bagalkot District 4.83 (3.49 – 6.68) <0.0001
Cotonou 3.16 (2.30 - 4.33) <0.0001
Kampala (Ref.) 1.00 - -
CCU‡ with primary partner in the past 7 days:
No 1.00 - -
Yes 0.68 (0.49 - 0.93) 0.0169
No primary partner or no sexual act with him 0.72 (0.56 - 0.92) 0.0085
Recent intra-vaginal cleansing (as reported at baseline) 1.30 (1.02 - 1.64) 0.0322
Candidiasis in the at-risk-period 0.70 (0.53 - 0.93) 0.0130
§ HR=Hazard ratio; ¶ CI=Confidence interval; ‡ CCU=Consistent condom use (100% of sexual acts).
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rate of RBV, though lower than in some previous studies
[24,25], among FSWs HIV seronegative at baseline. Some
common risk factors for a single BV episode were associ-
ated with RBV while others were not. Predictors of RBV
were primarily behavioural, particularly unprotected sex
with primary sex partner and recent intravaginal cleans-
ing. It is thus important to counsel high-risk women with
RBV about the adverse effects of vaginal cleansing and
the protective effects of condom use with all types of
partners.
The study site exhibited a consistently strong associ-
ation with RBV suggesting that research on risk factors
of this condition may need to be as well approached as a
socio-cultural environmental issue. Finally more pro-
spective studies, specifically designed to identify risk fac-
tors of RBV are still warranted.
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